Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Tax Provisions (2019 - 2023)

Historic Tax Provisions for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q1 2023 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Tax Provisions changed N/A to -$1.8 million in Q1 2023 from the same period last year, while for Dec 2023 it was -$1.8 million, marking a year-over-year increase of 8754.66%. This contributed to the annual value of -$1.8 million for FY2023, which is 43327.17% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Tax Provisions of -$1.8 million as of Q1 2023.
  • In the past 5 years, Lineage Cell Therapeutics' Tax Provisions registered a high of $4.4 million during Q1 2019, and its lowest value of -$14.0 million during Q4 2019.
  • Moreover, its 4-year median value for Tax Provisions was $541000.0 (2022), whereas its average is -$1.4 million.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Tax Provisions was 15345.85% (2022), while the steepest drop was 15345.85% (2022).
  • Lineage Cell Therapeutics' Tax Provisions (Quarter) stood at -$14.0 million in 2019, then skyrocketed by 92.78% to -$1.0 million in 2021, then surged by 153.46% to $541000.0 in 2022, then plummeted by 433.27% to -$1.8 million in 2023.
  • Its Tax Provisions stands at -$1.8 million for Q1 2023, versus $541000.0 for Q3 2022 and -$1.0 million for Q3 2021.